Archive for the ‘Arthritis’ Category

The Benefits Of Hip Replacement

Monday, December 3rd, 2007

Total hip arthroplasty (THA), or hip replacement, is an effective treatment for osteoarthritis (OA), but most studies have only followed patients for up to one year. A new study published in the December issue of Arthritis Care & Research examined patients after an average of eight years following hip replacement ...

GlaxoSmithKline And Genmab Initiate Ofatumumab Rheumatoid Arthritis Phase III Programme

Friday, November 23rd, 2007

GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced the initiation of the Phase III programme with ofatumumab to treat rheumatoid arthritis (RA). The programme will commence with two studies (OFA110635/GEN410 and OFA110634/GEN411), which will be conducted outside the US, in two distinct patient populations. One study will be in patients ...

Lack Of Critical Lubricant Causes Wear In Joints, First-Ever Study Finds

Wednesday, November 7th, 2007

Mice that don't produce lubricin, a thin film of protein found in the cartilage of joints, showed early wear and higher friction in their joints, a new study led by Brown University researchers shows. This link between increased friction and early wear in joints is a first; no other team of ...

First Topical Prescription Treatment For Osteoarthritis Pain, Voltaren Gel Receives FDA Approval

Tuesday, October 23rd, 2007

* First US approval for a prescription NSAID (non-steroidal anti-inflammatory drug) treatment that can be applied directly to site of osteoarthritis pain * Voltaren Gel is the only prescription topical medication proven to significantly reduce osteoarthritis pain in both the knees and the joints of the hands * Offers highly effective pain ...

Discovery Of 2 Genes Related To Disabling Form Of Arthritis

Monday, October 22nd, 2007

Work done in part by researchers at The University of Texas Medical School at Houston has led to the discovery of two genes that cause ankylosing spondylitis, an inflammatory and potentially disabling disease. The findings are published in the Oct. 21 online edition of Nature Genetics, a journal that emphasizes ...

Study Focuses On Cancer Risk In Biologic Treatment For Rheumatoid Arthritis

Sunday, September 2nd, 2007

The relationship between rheumatoid arthritis (RA), an autoimmune disease marked by chronic inflammation of the joints and tissue surrounding vital organs, and the incidence of cancer is complicated. Epidemiologic studies have generally demonstrated that blood, lung, and skin cancers are increased among RA patients, while breast and colon cancers are ...

Interleukin Genetics Initiates Study Of Genetics Of Osteoarthritis With New York University Medical Center

Friday, August 17th, 2007

Interleukin Genetics, Inc. (Amex: ILI) announced today that it has initiated a study on the genetics of osteoarthritis in collaboration with Dr. Steven Abramson, Director of the Division of Rheumatology at the Hospital for Joint Diseases of New York University Medical Center. Osteoarthritis (OA) is the breakdown of the cartilage cushion ...

Treating Osteoarthritis With Coxibs And NSAIDs

Thursday, August 16th, 2007

In an Editorial, to be published in the international journal Osteoarthritis and Cartilage (http://intl.elsevierhealth.com/journals/joca/), published by Elsevier, a panel of arthritis research experts has recommended that coxibs and nonsteroidal anti-inflammatory drugs (NSAIDs) must remain a significant part of the tool kit used in treating osteoarthritis (OA). The Editorial summarizes the ...

ORENCIA (Abatacept) Supplemental Biologics License Application For Juvenile Idiopathic Arthritis Accepted By FDA For Filing And Review

Thursday, August 9th, 2007

Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the supplemental biologics license application (sBLA) for ORENCIA (abatacept) for the treatment of pediatric patients with juvenile idiopathic arthritis (JIA) who have had an inadequate response to one or more ...